Schweizerischer Nationalfonds / Fonds national suisse
Storys zum Thema Krankheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- mehr
Huma, Camden Health Partners and UCLPartners launch digital-first population health programme to identify and manage cardiovascular disease
London (ots/PRNewswire) - - Aim is to prevent avoidable heart attacks and strokes in North London - Expands primary care capacity by utilising digital tools to identify and manage high risk individuals - Advances proactive, predictive care for people at risk of the world's leading cause of death1 Huma Therapeutics ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Avoiding burnout of white blood cells
mehrSchweizerische Multiple Sklerose Gesellschaft
2Swiss Multiple Sclerosis Society awards first MS research prize
mehrPlumCare RWE partners with Lifebit on Greece's newborn genomic sequencing program, BeginNGS
London (ots/PRNewswire) - - PlumCare RWE and Lifebit enter a three-year partnership to support Greece's pioneering national newborn genomic sequencing program, BeginNGS. - Researchers will be able to access and analyse data securely in combination with global cohorts, whilst ensuring data is kept safe, private and in place in their secure environment using Lifebit's ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Novel approaches to health care
mehrEagle Genomics' Scale-Up Funding from OMRON Ventures to Drive Sustainability Innovation in Microbiome R&D
Cambridge, England (ots/PRNewswire) - - OMRON Ventures joins existing investors abrdn, Environmental Technologies Fund and consortium led by Granpool Innovative Investments - Scale-up focused on enabling novel, sustainable scientific innovations that harness the microbiome to solve for 'One Health' challenges, ...
mehrLargest decentralised study of its kind shows high levels of engagement with Huma's study app
London (ots/PRNewswire) - - More than 90% of 2,524 participants invited to join a fully virtual COVID-19 study, run by Cambridge researchers, downloaded and registered on the study app1 - Around 75% of participants completed digital biomarker assessments such as resting heart rate, temperature and oxygen saturation at least once per week1 - Participants were aged 45 - ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
mehrMars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
New York (ots/PRNewswire) - - The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care - Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future ...
mehrHuma to provide best-in-class digital clinical trials solutions through landmark acquisition of Alcedis
London and Frankfurt, Germany (ots/PRNewswire) - - Acquisition combines award-winning digital health platform with global clinical research expertise acquired over 25 years - Creates new and advanced digital solutions across all phases of clinical trials - Accelerates patient recruitment and the development of new ...
mehrCirculating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Huntingdon Valley, Pa. (ots/PRNewswire) - Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with ...
mehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrLUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference ...
mehrEagle Genomics Announces USD 20M First Close; Scale-up Funding to Accelerate the Application of Microbiome Science for Global 'One Health' Innovation
Cambridge, England (ots/PRNewswire) - - Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion - Platform business focused on bridging the current 'translation gap', addressing critical bottlenecks in the ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Improving the efficacy of antibiotics and curbing resistance
Bern (ots) - New findings from NRP 72, financed by the Swiss National Science Foundation, are helping to curb antibiotic resistance. In the field of new antibiotics, however, structures needed for translating results into practice are lacking. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. As antibiotics lose their efficacy, infections that were once easy to treat can give rise to fatal ...
mehrLumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
London (ots/PRNewswire) - Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa - Early customers include GP offices and other community-based healthcare settings - Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly ...
mehrTauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
mehrTauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
mehrMedison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
Petach Tikvah, Israel (ots/PRNewswire) - With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. Medison Pharma ("Medison"), a global pharma company focused on providing access to ...
mehrTES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis
Perugia, Italy (ots/PRNewswire) - INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and ...
mehrForging a healthier future through research: McGill University launches new Institute of Genomic Medicine
Montreal (ots/PRNewswire) - Landmark donation from alumnus Dr. Victor Phillip Dahdaleh will accelerate advances in global health using genomic medicine to inform patient diagnosis and care A landmark donation to support McGill University's renowned genomics research and education programs from UK-based alumnus and ...
mehrThe International Osteoporosis Foundation (IOF)
On World Osteoporosis Day, take five steps to better bone health
mehrMenarini Silicon Biosystems's CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination
Huntingdon Valley, Pa. (ots/PRNewswire) - These new codes are required to access Medicare/Medicaid insurance reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 Circulating Tumor Cell (CTC-HER2) assays, to monitor disease status in patients with life-threatening illnesses. Menarini ...
mehrPharming submits a Marketing Authorisation Application to the European Medicines Agency for Leniolisib
Leiden, Netherlands (ots/PRNewswire) - Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of accelerated assessment allowing an expedited review for leniolisib from a standard 210 days ...
mehrEvonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
Essen, Germany (ots/PRNewswire) - - Evonik to produce commercial quantities of the drug substance vonoprazan for use in VOQUEZNA™ TRIPLE PAK™ and DUAL PAK™, and other products containing vonoprazan - Supply security through production at sites in Europe and North America - Agreement strengthens Evonik's track record as leading contract development and ...
mehrServier unveils its 2030 ambition and reveals a new visual identity
Paris (ots/PRNewswire) - - A new ambition by 2030 to accelerate its transformation dynamic - A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing visible results. The Group intends to accelerate its transformation dynamics in order ...
mehrDEBIOPHARM REINFORCES THE BOND BETWEEN SWISS AND JAPANESE CANCER RESEARCH WITH THE 2022 JCA MAUVERNAY AWARD CEREMONY
Lausanne, Switzerland (ots) - Debiopharm awards the winning scientists for the JCA (Japanese Cancer Association) Award for innovative, disruptive, and translational oncology research Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, today announced the two winners of JCA Mauvernay ...
mehrPHARMANOVIA ENTERS EXCLUSIVE LICENSING COLLABORATION FOR DIAZEPAM BUCCAL FILM
London (ots/PRNewswire) - - PHARMANOVIA EXCLUSIVELY LICENCES RIGHTS FOR A NOVEL WAY OF TREATING ACUTE EPILEPSY SEIZURE CLUSTERS IN EUROPE, MIDDLE EAST AND NORTH AFRICA - PATENTED BUCCAL FILM TECHNOLOGY HAS THE POTENTIAL TO IMPROVE THE EASE OF ADMINISTRATION FOR CAREGIVERS, PATIENTS AND HCPs Pharmanovia, the lifecycle management company, has today announced that it has ...
mehr